Home › Companies › Tarsus Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed June 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 25, 2026: 6 items on Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed June 29, 2026: 4 elected · 2 approved.
Significant dissent: 1 director (23.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Tang Capital (13F, 3.9%, as of September 30, 2026)
Explore Tarsus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Tarsus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Wendy Yarno, MBA | 34,398,690 | -- | -- | 374,956 | 3,463,568 | 99% | Elected | — |
| Elect Director: Andrew Goldberg, M.D. | 26,733,789 | -- | -- | 8,039,857 | 3,463,568 | 77% | Elected | — |
| Elect Director: Scott Morrison | 34,225,471 | -- | -- | 548,175 | 3,463,568 | 98% | Elected | — |
| Elect Director: David E.I. Pyott, MBA | 33,612,963 | -- | -- | 1,160,683 | 3,463,568 | 97% | Elected | — |
| 2. Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy Statement. The | 34,486,767 | 238,014 | 48,865 | -- | 3,463,568 | 99.3% | Approved | — |
| 3. Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm | 38,219,521 | 3,651 | 14,042 | -- | -- | 99.9% | Approved | — |
Source: Tarsus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 29, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
292 asset managers disclosed a vote on at least one Tarsus Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Andrew Goldberg
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Andrew Goldberg, M.D.”): 26,733,789 for, 8,039,857 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 9,333,289 for, 2,236,585 withheld, 17 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,084,408 | 0 | 17 | 23,250 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,286,608 | 0 | 0 | 18,000 | For |
| Prudential/PGIM | 667,367 | 0 | 0 | 98,272 | Mixed |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 273,131 | Withhold |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 261,461 | Withhold |
| Loomis Sayles | 0 | 0 | 0 | 222,303 | Withhold |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 174,580 | Withhold |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 120,498 | Withhold |
| Equitable | 91,148 | 0 | 0 | 25,540 | Mixed |
| First Trust | 0 | 0 | 0 | 110,377 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 100,000 | Withhold |
| State Street | 97,305 | 0 | 0 | 65 | For |
| Bridge Builder Trust | 34,384 | 0 | 0 | 55,134 | Mixed |
| MoA Funds Corp | 0 | 0 | 0 | 67,022 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 0 | 0 | 0 | 59,777 | Withhold |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: David E.I. Pyott
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David E.I. Pyott, MBA”): 33,612,963 for, 1,160,683 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 10,693,047 for, 876,840 withheld, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,672 | 0 | 3 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 273,131 | Withhold |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 0 | 0 | 222,303 | Withhold |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 10,117 | 0 | 0 | 137,201 | Mixed |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 100,000 | Withhold |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 59,777 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Scott Morrison
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Scott Morrison”): 34,225,471 for, 548,175 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 11,557,159 for, 12,730 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,105,824 | 0 | 1 | 1,850 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 59,777 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Wendy Yarno
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy Yarno, MBA”): 34,398,690 for, 374,956 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 11,566,635 for, 3,254 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,674 | 0 | 1 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 59,777 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
99.3% Approved · of votes cast
Description as filed by funds: To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy S”): 34,486,767 for, 238,014 against — passed, per its Form 8-K filed June 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,674 | 0 | 0 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 100,981 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
Fund voting reports, all 87 managers: 11,609,988 for, 3,272 against, 33,254 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 4,604,707 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 3,557,678 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 3,346,025 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 2,002,080 | 0 | 0 | 0 | For |
| Invesco | 1,666,003 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 1,399,098 | 0 | 0 | 0 | For |
| BlackRock | 1,374,163 | 195 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,025,721 | 0 | 0 | 0 | For |
| State Street | 881,939 | 1,255 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 728,644 | 0 | 0 | 0 | For |
| Fidelity | 703,822 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 685,216 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 543,961 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 499,306 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 493,320 | 0 | 0 | 0 | For |
| Loomis Sayles | 393,994 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 356,340 | 0 | 0 | 0 | For |
| Charles Schwab | 329,603 | 0 | 0 | 0 | For |
| Northern Trust | 324,895 | 0 | 0 | 0 | For |
| Vanguard | 318,838 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 316,595 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,687 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 307,504 | 0 | 0 | 0 | For |
| Nuveen | 283,246 | 0 | 0 | 0 | For |
| Artisan | 264,197 | 0 | 0 | 0 | For |
Institutional-manager reports, all 233 managers: 30,687,848 for, 124,712 against, 24,951 abstained, 180 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 99.6% for (June 12, 2025 meeting) ▲ 0.3 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm”): 38,219,521 for, 3,651 against — passed, per its Form 8-K filed June 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm The Company's stockholders approved the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 11,566,636 for, 3,254 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,675 | 0 | 0 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 59,777 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,021,312 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.90% |
| 2 | BlackRock | 3.69% |
| 3 | Fidelity | 3.03% |
| 4 | Prudential/PGIM | 1.78% |
| 5 | JANUS INVESTMENT FUND | 1.72% |
| 6 | Lord Abbett | 1.17% |
| 7 | Legg Mason | 1.03% |
| 8 | Invesco | 1.03% |
| 9 | Charles Schwab | 0.77% |
| 10 | Waddell & Reed | 0.63% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 10.70% |
| 2 | Deep Track Capital, LP | 8.27% |
| 3 | RTW INVESTMENTS, LP | 7.78% |
| 4 | Paradigm Biocapital Advisors LP | 4.65% |
| 5 | Invesco | 3.87% |
| 6 | JENNISON ASSOCIATES LLC | 3.25% |
| 7 | BlackRock | 3.19% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.38% |
| 9 | State Street | 2.05% |
| 10 | Frazier Life Sciences Management, L.P. | 1.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Deep Track Capital, LP | 3,600,000 | 8.37% | Schedule 13G, filed May 15, 2026 |
| BlackRock | 3,552,612 | 8.26% | Form 13F, quarter ended March 31, 2026 |
| RTW Investments, LP | 3,424,180 | 7.96% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Paradigm BioCapital Advisors LP | 2,440,445 | 5.67% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Vanguard Group | 2,399,560 | 5.58% | Form 13F, quarter ended March 31, 2026 |
| JANUS HENDERSON GROUP PLC | 2,240,963 | 5.21% | Schedule 13G, filed May 15, 2026 |
| Bobak Azamian | 2,221,102 | 5.16% | Proxy statement (DEF 14A), proxy filed April 28, 2026 |
| Morgan Stanley | 2,040,742 | 4.74% | Form 13F, quarter ended March 31, 2026 |
| PRUDENTIAL FINANCIAL INC | 1,836,321 | 4.27% | Schedule 13G, filed May 8, 2026 |
| Jennison Associates LLC | 1,712,124 | 3.98% | Schedule 13G, filed May 6, 2026 |
Percentages above are of 43,021,312 shares outstanding, as reported by Tarsus Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Tarsus Pharmaceuticals, Inc.'s shareholder meeting held June 25, 2026, in the 2025-2026 proxy season, 292 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,852 separate fund positions. On the most widely held item on that ballot — To hold an advisory vote to approve, on a non-binding basis, our named executive officer… — Tarsus Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 99.3% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Tarsus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 29, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Tarsus Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Tarsus Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Tarsus Pharmaceuticals (TARS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/tarsus-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.